[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![ABBONews Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::102177005.png) ABBO News [@ABBONews](/creator/twitter/ABBONews) on x 13.9K followers
Created: 2025-07-17 12:26:23 UTC

🚨 Fresh Analyst Take: Mizuho has reaffirmed its "Outperform" rating and $XX price target on Sarepta Therapeutics $SRPT, citing reduced concerns over a potential FDA market withdrawal of its Elevidys treatment.

![](https://pbs.twimg.com/media/GwDzJD6XwAAKcO9.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945822386290389318/c:line.svg)

**Related Topics**
[$srpt](/topic/$srpt)
[sarepta therapeutics](/topic/sarepta-therapeutics)
[sarepta therapeutics inc](/topic/sarepta-therapeutics-inc)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/ABBONews/status/1945822386290389318)